Synthesis and anti-tumor activity evaluation of a novel series of dithiocarbamates bearing 1,2,3-triazole and [1-Bi(4-fluorophenyl)methyl]piperazine unit was written by Mo, Song;Ding, Yong;Zhang, Gang;Zhang, Zhen;Shao, Xuebei;Li, Qinghan;Yang, Xuejun;Chen, Feng. And the article was included in Youji Huaxue in 2017.Formula: C17H18F2N2 This article mentions the following:
Sixteen novel dithiocarbamates containing 1,2,3-triazole and [1-bi(4-fluorophenyl)methyl]piperazine group were prepared via two steps starting from [1-bis(4-fluorophenyl)methyl]piperazine, propargyl bromide, methanedithione and sodium azide, using a very simple catalytic system composed of 5 mol% copper(I) iodide and MDF-H2O (V:V = 1:1) as solvent at 70°C for 4 h with moderate yield (34%-65%). The structures of the new compounds were characterized by IR, MS, 1H NMR, 13C NMR and element anal. The bioactive assay for the newly prepared compounds manifested that fourteen dithiocarbamate derivatives exhibited good to excellent inhibitory activity against CDC25B in 20μg/mL (inhibitory rate up to 97.96%, IC50 value up to 11.55μg/mL), and six dithiocarbamate derivatives exhibited excellent inhibitory activity against leukemia HL-60 and lung cancer A-549 cell in 40μmol·L-1 (inhibitory rate up to 99.99% and 93.91%, resp.; IC50 value up to 12.11 and 22.45μg/mL, resp.). In the experiment, the researchers used many compounds, for example, 4,4-Difluorobenzhydrylpiperazine (cas: 27469-60-9Formula: C17H18F2N2).
4,4-Difluorobenzhydrylpiperazine (cas: 27469-60-9) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Formula: C17H18F2N2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics